Analysts name Boston Scientific among other companies as ripe for acquisition
This article was originally published in Clinica
Executive Summary
Boston Scientific is one of the most likely targets for acquisition by another company this year, according to one industry analyst. In his Medical Products 1999 Outlook report dated December 31, Hambrecht & Quist's senior analyst, Robert Faulkner, wrote that the company was one of the most likely targets for acquisition or merger, possibly by Johnson & Johnson.